- Metastatic melanoma successfully treated with Ipilimumab2012 | Third Faculty of Medicine
- Possible Pitfalls of Ipilimumab Therapy in Malignant Melanoma - a Case Report2015 | Faculty of Medicine in Hradec Králové
- Complete remission of two patients with metastatic melanoma on ipilimumab2012 | Publication without faculty affiliation
- Comments on the Clinical Development of Ipilimumab2013 | Publication without faculty affiliation
- Nivolumab plus chemotherapy or ipilimumab in the first-line palliative therapy of esophageal, gastroesophageal junction, and gastric cancer2023 | Faculty of Medicine in Hradec Králové
- Immediate and Durable Response to Ipilimumab Therapy in Malignant Melanoma. A Case Report of 31 Months Sustained Response2013 | Publication without faculty affiliation
- Slow Progression of Liver Metastases Following Previous Ipilimumab Induced Stable Disease in Melanoma of Choroid. A Case Report2013 | Publication without faculty affiliation
- Report of University Hospital Hradec Králové to the clinical trial protocol No: CA209-067Publication without faculty affiliation
- Výzkumná zpráva Fakultní nemocnice ke klinickému Hodnocení CA209-067Publication without faculty affiliation
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. CA209-238Publication without faculty affiliation
- IIpilimumab in the treatment of melanoma2014 | Third Faculty of Medicine
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. CA209-214Publication without faculty affiliation
- Treatment possibilities of ipilimumab-induced thrombocytopenia-case study and literaure review2015 | Faculty of Medicine in Hradec Králové
- Malignant melanoma2013 | Third Faculty of Medicine
- Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma2015 | Third Faculty of Medicine
- Development of chronic lymphocytic leukaemia during ipilimumab therapy in a patient with metastatic melanoma2016 | Third Faculty of Medicine, Second Faculty of Medicine
- Význam blokády CTLA-4 v léčbě onkologických onemocnění: ipilimumab, monoklonální protilátka tlumící imunosupresivní signální aktivitu CTLA-42021 | First Faculty of Medicine
- Ipilimumab for the treatment of metastatic prostate cancer2018 | Second Faculty of Medicine
- Failure of adjuvant treatment for malignant melanoma - what next?2021 | Publication without faculty affiliation
- Advances in Immunotherapy of Malignant Melanoma2017 | Publication without faculty affiliation
- Nivolumab + ipilimumab v kombinaci s dvěma cykly chemoterapie u pacientky s karcinomem plic a pleurálním výpotkem2023 | Faculty of Medicine in Pilsen
- The Year 2011 is the Year of Melanoma: Melanoma Forum, Frankfurt, 19. May 20112011 | Faculty of Medicine in Hradec Králové
- Neurotoxicity and immunotherapy2020 | Publication without faculty affiliation
- Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial2020 | Third Faculty of Medicine
- Melanoma antigens are biomarkers for ipilimumab response2017 | Third Faculty of Medicine, Central Library of Charles University
- Nivolumab in the treatment of metastatic melanoma2015 | Publication without faculty affiliation
- Komentář ke studii (Nivolumab a ipilimumab u pacientů s NSCLC s vysokou mutační zátěží - studie CheckMate 227)2018 | First Faculty of Medicine
- Kompletní remise metastáz melanomu po kombinované léčbě ipilimumabem a nivolumabem u pacientky s hypofyzitidou vyvolanou imunoterapií2021 | First Faculty of Medicine
- Current possibilities of immunotherapy in the treatment of malignant melanoma2018 | Faculty of Medicine in Hradec Králové
- Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria2022 | Third Faculty of Medicine